Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cidara Thera (NQ: CDTX )

1.510 +0.150 (+11.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cidara Thera

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets. 
Via Benzinga
Looking Into Cidara Therapeutics's Return On Capital Employed
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
From Cidara Therapeutics, Inc.
Via Globe NewsWire
Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review
 
Via Benzinga
Recap: Cidara Therapeutics Q2 Earnings
  Cidara Therapeutics (NASDAQ:CDTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million. 
Via Benzinga
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
From Cidara Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CinCor Pharma (NASDAQ:CINC) shares moved upwards by 19.5% to $33.0 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 billion. 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
 
Via Benzinga
With FDA Submission, Cidara Therapeutics Inks US Pact For Bloodstream Infection Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
  
Via Benzinga
Short Volatility Alert: Cidara Therapeutics, Inc.
On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72. The overall sentiment for CDTX has... 
Via Benzinga
Short Volatility Alert: Cidara Therapeutics, Inc.
On Friday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.785. The overall sentiment for CDTX has been... 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Cidara Pursues FDA Approval For Bloodstream Infections Candidate
Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and... 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
From Cidara Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 9.4% to $0.81 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.